EP0835106A4 - Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten - Google Patents

Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten

Info

Publication number
EP0835106A4
EP0835106A4 EP96921794A EP96921794A EP0835106A4 EP 0835106 A4 EP0835106 A4 EP 0835106A4 EP 96921794 A EP96921794 A EP 96921794A EP 96921794 A EP96921794 A EP 96921794A EP 0835106 A4 EP0835106 A4 EP 0835106A4
Authority
EP
European Patent Office
Prior art keywords
renal disease
ace inhibitor
treating renal
aii antagonist
aii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96921794A
Other languages
English (en)
French (fr)
Other versions
EP0835106A1 (de
Inventor
Giuseppe Remuzzi
Ronald S Eydelloth
Roger A Owen
Shahnaz Shahinfar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Merck Sharp and Dohme Chibret SAS
Merck and Co Inc
Original Assignee
Laboratories Merck Sharp and Dohme Chibret SAS
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602854.3A external-priority patent/GB9602854D0/en
Application filed by Laboratories Merck Sharp and Dohme Chibret SAS, Merck and Co Inc filed Critical Laboratories Merck Sharp and Dohme Chibret SAS
Publication of EP0835106A1 publication Critical patent/EP0835106A1/de
Publication of EP0835106A4 publication Critical patent/EP0835106A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP96921794A 1995-06-30 1996-06-26 Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten Withdrawn EP0835106A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77095P 1995-06-30 1995-06-30
US770P 1995-06-30
GBGB9602854.3A GB9602854D0 (en) 1996-02-13 1996-02-13 Method of treating renal disease using an ace inhibitor and an II antagonist
GB9602854 1996-02-13
PCT/US1996/010942 WO1997002032A1 (en) 1995-06-30 1996-06-26 Method of treating renal disease using an ace inhibitor and an aii antagonist

Publications (2)

Publication Number Publication Date
EP0835106A1 EP0835106A1 (de) 1998-04-15
EP0835106A4 true EP0835106A4 (de) 1998-09-30

Family

ID=26308665

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96921794A Withdrawn EP0835106A4 (de) 1995-06-30 1996-06-26 Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten

Country Status (5)

Country Link
EP (1) EP0835106A4 (de)
JP (1) JPH11508894A (de)
AU (1) AU716519B2 (de)
CA (1) CA2224451A1 (de)
WO (1) WO1997002032A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283348B6 (sk) * 1996-04-05 2003-06-03 Takeda Chemical Industries, Ltd. Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II
WO2001060362A1 (en) * 2000-02-18 2001-08-23 Takeda Chemical Industries, Ltd. TNF-α INHIBITORS
EP1326604A2 (de) * 2000-04-12 2003-07-16 Novartis AG Kombination von mindestens 2 aus einer at1-rezeptoren-antagonist- oder einer ace-inhibitor- oder einer hmg-co-a reduktase inhibitorgruppe selektierte wirkstoffe
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
JP2004520268A (ja) * 2000-08-22 2004-07-08 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト アンギオテンシンｉｉ拮抗剤とアンギオテンシンｉ変換酵素阻害剤とを含有する医薬組成物
ES2309187T3 (es) * 2001-08-31 2008-12-16 Australian Biomedical Company Pty Ltd Preparacion y uso de giberelinas para tratar la diabetes.
EP1438027A1 (de) 2001-10-25 2004-07-21 DepoMed, Inc. Behandlungsmethode unter verwendung einer losartan enthaltenden darreichungsform mit verlängerter magenverweilzeit
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
EP1452176A4 (de) * 2001-12-03 2009-01-21 Takeda Pharmaceutical Mittel zur verbesserung der insulinresistenz
DE10229180A1 (de) * 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
US20060217421A1 (en) * 2003-05-09 2006-09-28 Hajimu Kurumatani Fortifier
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
PT2800738T (pt) 2012-01-06 2020-06-23 Novartis Ag Compostos heterocíclicos e métodos para a utilização dos mesmos
CN116637115A (zh) * 2017-05-27 2023-08-25 广州喜鹊医药有限公司 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017771A1 (en) * 1990-05-11 1991-11-28 Pfizer Inc. Synergistic therapeutic compositions and methods
WO1992010097A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
EP0527534A1 (de) * 1991-08-13 1993-02-17 Merck & Co. Inc. Chinolin- und Azachinolin-Derivate als Angiotensin-II-Antagonisten
EP0537937A2 (de) * 1991-10-07 1993-04-21 Merck & Co. Inc. Substituierte Pyrazino (2,3-D)Pyrimidinone als Angiotensin-II Antagoniste
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
WO1996031234A1 (en) * 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
WO1997037688A2 (en) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017771A1 (en) * 1990-05-11 1991-11-28 Pfizer Inc. Synergistic therapeutic compositions and methods
WO1992010097A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
EP0527534A1 (de) * 1991-08-13 1993-02-17 Merck & Co. Inc. Chinolin- und Azachinolin-Derivate als Angiotensin-II-Antagonisten
EP0537937A2 (de) * 1991-10-07 1993-04-21 Merck & Co. Inc. Substituierte Pyrazino (2,3-D)Pyrimidinone als Angiotensin-II Antagoniste
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
WO1996031234A1 (en) * 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
WO1997037688A2 (en) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURDMANN ET AL: "Prevention of Experimental Cyclosporin-Induced Interstitial Fibrosis by Losartan and Enalapril", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 269, no. 4, October 1995 (1995-10-01), pages f491 - f499, XP002072709 *
POLLOCK ET AL: "Angiotensin II Receptor Blockade Improves Renal Function in Rats with Reduced Renal Mass", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 367, no. 2, 1993, pages 657 - 663, XP002072710 *
See also references of WO9702032A1 *

Also Published As

Publication number Publication date
CA2224451A1 (en) 1997-01-23
AU6291696A (en) 1997-02-05
EP0835106A1 (de) 1998-04-15
WO1997002032A1 (en) 1997-01-23
AU716519B2 (en) 2000-02-24
JPH11508894A (ja) 1999-08-03

Similar Documents

Publication Publication Date Title
ZA965088B (en) Methods of preventing or treating allergles
GB2342111B (en) Emulsion for well and formation treatment
ZA982206B (en) Tampon and method of making same
EP0866683A4 (de) Mittel und verfahren zur behandlung erkrankter nägel
ZA965786B (en) Nonwoven barrier and method of making the same
IL138871A0 (en) Flushable diaper and method
EP0835106A4 (de) Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten
EP0796093A4 (de) Verbindungen und verfahren zur hemmung von phosphodiesterase iv
IL117988A0 (en) A new combination of an inhibitor and an antagonist
ZA979806B (en) Bill validator of master-slave type and method for down-load of validator
PL322652A1 (en) Compounds of pyrolydinylohydroxamic acid and method of obtaining them
PL327600A1 (en) Method of treating depressions
AU7257696A (en) Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
PL331766A1 (en) Method of inhibiting fas expression
PL337716A1 (en) Method of obtaining thiazafurin and other c-nucleosides
EP0777426A4 (de) Mokassinausführung und verfahren zu seiner herstellung
EP1113808A4 (de) Ein behandlungsverfahren sowie hierfür geeignete agenzien
NO965497D0 (no) Fremgangsmåte for kontrollert fiksering av skallinhibitor i en underjordisk formasjon
AU6168296A (en) Chloroquine analogs and methods of preventing and treating p lasmodial disease
GB9602854D0 (en) Method of treating renal disease using an ace inhibitor and an II antagonist
GB9524267D0 (en) Enzyme inhibitor and method
PL317598A1 (en) Drill and method of making same
IL114096A0 (en) Methods of treating hypertension and improving impaired renal function
GB9405905D0 (en) Inhibitors of isoprenylated protein endoprotease
PL327997A1 (en) Methods of obtaining 1-(2-[-isoxazol-3-yl benzofuran-5-yloxy]ethylamine-3-phenoxy 2-(s)-ole and intermediate compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHAHINFAR, SHAHNAZ

Inventor name: OWEN, ROGER, A.

Inventor name: EYDELLOTH, RONALD, S.

Inventor name: REMUZZI, GIUSEPPE

A4 Supplementary search report drawn up and despatched

Effective date: 19980814

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010103